New Norvir™ capsules get the nod in Europe

Estimated reading time 1 minutes
This article is more than 24 years old.

The new soft capsule formulation of ritonavir

(Norvir™) has passed through the first stage of the European Union licensing

procedure after the Committee for Proprietary Medicinal Products (CPMP) adopted

Glossary

named patient basis prescribing

A means of access to an unlicensed drug, in which a doctor requests supplies from its manufacturer for a specific individual.

formulation

The physical form in which a drug is manufactured or administered. Examples of formulations include tablets, capsules, powders, and oral and injectable solutions. A drug may be available in multiple formulations.

a positive opinion on its approval last week. The European Commission are

expected to 'rubber stamp' this decision by mid-November, allowing the

prescription of ritonavir capsules throughout the UK and other member

states.

Until then, manufacturers Abbott Labs are making the new capsules

widely available through a named patient programme. For more details of this

scheme, doctors should contact Abbott on 01628 644370.

For further

information see aidsmap's

href="http://www.aidsmap.com/article.asp?articleID=361&heading3=Ritonavir+%2D+overview">ritonavir

overview

.

Print